PT2115472E - Biomarcadores de cancro - Google Patents

Biomarcadores de cancro Download PDF

Info

Publication number
PT2115472E
PT2115472E PT78486313T PT07848631T PT2115472E PT 2115472 E PT2115472 E PT 2115472E PT 78486313 T PT78486313 T PT 78486313T PT 07848631 T PT07848631 T PT 07848631T PT 2115472 E PT2115472 E PT 2115472E
Authority
PT
Portugal
Prior art keywords
cancer biomarkers
biomarkers
cancer
Prior art date
Application number
PT78486313T
Other languages
English (en)
Inventor
Hardev Pandha
Richard George Leonard Morgan
Original Assignee
Univ Surrey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Surrey filed Critical Univ Surrey
Publication of PT2115472E publication Critical patent/PT2115472E/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
PT78486313T 2006-12-19 2007-12-19 Biomarcadores de cancro PT2115472E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0625321.5A GB0625321D0 (en) 2006-12-19 2006-12-19 Cancer biomarker
GBGB0719792.4A GB0719792D0 (en) 2006-12-19 2007-10-10 Cancer biomarkers

Publications (1)

Publication Number Publication Date
PT2115472E true PT2115472E (pt) 2014-02-14

Family

ID=39265269

Family Applications (1)

Application Number Title Priority Date Filing Date
PT78486313T PT2115472E (pt) 2006-12-19 2007-12-19 Biomarcadores de cancro

Country Status (19)

Country Link
US (1) US8460882B2 (pt)
EP (1) EP2115472B1 (pt)
JP (1) JP5683108B2 (pt)
CN (1) CN101675341B (pt)
AU (1) AU2007335999B2 (pt)
BR (1) BRPI0720371B8 (pt)
CA (1) CA2671939C (pt)
CY (1) CY1115178T1 (pt)
DK (1) DK2115472T3 (pt)
ES (1) ES2445185T3 (pt)
GB (2) GB0625321D0 (pt)
IL (1) IL199241A (pt)
MX (1) MX2009006378A (pt)
NZ (1) NZ577548A (pt)
PL (1) PL2115472T3 (pt)
PT (1) PT2115472E (pt)
RU (1) RU2460075C2 (pt)
SI (1) SI2115472T1 (pt)
WO (1) WO2008075056A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8461126B2 (en) 2005-10-14 2013-06-11 Phigenix, Inc. Targeting EN2, PAX2, and/or DEFB1 for treatment of prostate conditions
DE102006047617B4 (de) 2006-10-09 2008-11-27 Clariant International Limited Verfahren zur Herstellung basischer (Meth)acrylamide
DE102008017216B4 (de) 2008-04-04 2013-08-14 Clariant International Ltd. Kontinuierliches Verfahren zur Herstellung von Fettsäureamiden
GB0823445D0 (en) * 2008-12-23 2009-01-28 Univ Surrey Biomarker
DE102009031059A1 (de) 2009-06-30 2011-01-05 Clariant International Ltd. Vorrichtung zur kontinuierlichen Durchführung chemischer Reaktionen bei hohen Temperaturen
GB0912175D0 (en) * 2009-07-13 2009-08-26 Univ Surrey Biomarker
CN102549433A (zh) * 2009-07-13 2012-07-04 萨里大学 治疗肽、多肽和核酸序列
GB0912190D0 (en) * 2009-07-13 2009-08-26 Univ Surrey Biomarker
DE102009042522A1 (de) 2009-09-22 2011-04-07 Clariant International Ltd. Kontinuierliches Umesterungsverfahren
DE102009042523B4 (de) 2009-09-22 2012-02-16 Clariant International Ltd. Vorrichtung und Verfahren zur kontinuierlichen Durchführung heterogen katalysierter chemischer Reaktionen bei hohen Temperaturen
GB0921329D0 (en) * 2009-12-04 2010-01-20 Univ Surrey Biomarker
DE102010056565A1 (de) 2010-12-30 2012-07-05 Clariant International Ltd. Verfahren zur Modifizierung Hydroxylgruppen tragender Polymere
US20140106363A1 (en) * 2011-05-12 2014-04-17 Noviogendix Research B.V. Molecular markers in prostate cancer
WO2012152800A1 (en) * 2011-05-12 2012-11-15 Noviogendix Research B.V. Molecular markers in prostate cancer
WO2013037118A1 (zh) * 2011-09-16 2013-03-21 上海长海医院 ***癌的生物学标志物、治疗靶点及其用途
WO2013085483A1 (en) * 2011-12-05 2013-06-13 Phigenix, Inc. Targeting en2, pax2, and/or defb1 for treatment of prostate conditions
US9110030B2 (en) 2012-06-29 2015-08-18 Daniel A. Kerschensteiner Colorimetric gelatinase assay
US10613087B2 (en) * 2012-08-10 2020-04-07 Analiza, Inc. Methods and devices for analyzing species to determine diseases
CA2910327A1 (en) * 2013-05-09 2014-11-13 Rui Li Method and system for assessing health condition
WO2016102560A1 (en) * 2014-12-23 2016-06-30 The University Of Surrey Glycosylated biomarker
KR101698654B1 (ko) * 2014-12-24 2017-01-20 포항공과대학교 산학협력단 En2에 특이적으로 결합하는 dna 압타머 및 이의 용도
US11827938B2 (en) * 2015-05-29 2023-11-28 Koninklijke Philips N.V. Methods of prostate cancer prognosis
CN108289929A (zh) * 2015-09-23 2018-07-17 国家科学研究中心 用于治疗神经退行性障碍的同源异型蛋白
CN106282347A (zh) * 2016-08-17 2017-01-04 中南大学 HoxC11作为生物标志物在制备肺腺癌的预诊断试剂中的应用
CN106795496B (zh) * 2016-12-28 2019-01-18 中国科学院广州生物医药与健康研究院 一种获得t细胞的方法及应用
KR101777085B1 (ko) * 2017-02-23 2017-09-11 주식회사 성균바이오텍 En2 단백질의 면역원성 단편 펩타이드 또는 이를 특이적으로 인식하는 항체 조성물
KR101777254B1 (ko) * 2017-07-14 2017-09-13 주식회사 무진메디 En2 단백질을 특이적으로 인식하는 특정 항원으로부터 얻어진 단클론 항체 또는 이를 함유하는 전립선암 진단용 조성물
KR101777259B1 (ko) * 2017-07-14 2017-09-13 주식회사 무진메디 En2 단백질을 특이적으로 인식하는 단클론 항체 또는 이를 함유하는 전립선암 진단용 조성물
CN107894507A (zh) * 2017-11-22 2018-04-10 南宁科城汇信息科技有限公司 一种发现和鉴定肝癌血清差异表达蛋白和验证标志物蛋白方法
CN107727729A (zh) * 2017-11-22 2018-02-23 南宁科城汇信息科技有限公司 一种oa候选标志物诊断模型的建立方法
KR101923199B1 (ko) 2018-04-25 2018-11-28 주식회사 무진메디 펩스타틴 a를 함유하는 소변 내 en2 진단용 조성물
CN111363817B (zh) * 2018-12-26 2024-02-02 广州康立明生物科技股份有限公司 基于hoxd12基因的肺癌诊断剂及试剂盒

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0996725A1 (en) * 1997-06-27 2000-05-03 Human Genome Sciences, Inc. Human nk-3 related prostate specific gene-1
RU2234942C2 (ru) * 1998-07-14 2004-08-27 Корикса Корпорейшн Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид
WO2000023111A1 (en) * 1998-10-19 2000-04-27 Diadexus Llc Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
US20040029208A1 (en) 2000-05-30 2004-02-12 Ravn Helle Weber Assay method and kit for testing biological material for exposure to stress using biomarkers
WO2002000926A2 (en) * 2000-06-30 2002-01-03 Epigenomics Ag Diagnosis of diseases associated with signal transduction
AU2001292718A1 (en) * 2000-09-12 2002-03-26 Transgenetics Incorporated Microarrayed organization of transcription factor target genes
US20040063216A1 (en) 2000-12-24 2004-04-01 Iser Lubocki Method for detecting biomarkers
WO2002054936A2 (en) 2000-12-24 2002-07-18 Kohn, Kenneth, I. A method for detecting biomarkers
EP1364069B1 (en) * 2001-03-01 2009-04-22 Epigenomics AG Method for the development of gene panels for diagnostic and therapeutic purposes based on the expression and methylatoin status of the genes
US6949342B2 (en) * 2001-12-21 2005-09-27 Whitehead Institute For Biomedical Research Prostate cancer diagnosis and outcome prediction by expression analysis
CA2469089A1 (en) * 2003-07-08 2005-01-08 Institut De Recherches Cliniques De Montreal En-2 gene, disgnostic and therapeutic uses thereof
US20060014301A1 (en) 2004-07-13 2006-01-19 Power3 Medical Products, Inc. Antibody-based system for detection of differential protein expression patterns
EP2213749A1 (en) * 2004-12-02 2010-08-04 Epigenomics AG Methods and nucleic acids for the analysis of gene expression associated with the prognosis of prostate cell proliferative disorders
WO2006089091A2 (en) 2005-02-18 2006-08-24 Memorial Sloan-Kettering Cancer Center Methods for detecting minimum residual disease

Also Published As

Publication number Publication date
CN101675341A (zh) 2010-03-17
EP2115472B1 (en) 2013-11-06
JP2010513901A (ja) 2010-04-30
JP5683108B2 (ja) 2015-03-11
RU2460075C2 (ru) 2012-08-27
DK2115472T3 (da) 2014-02-10
GB0719792D0 (en) 2007-11-21
BRPI0720371B1 (pt) 2019-05-28
AU2007335999B2 (en) 2013-09-05
US20100093558A1 (en) 2010-04-15
WO2008075056A1 (en) 2008-06-26
IL199241A (en) 2014-03-31
BRPI0720371B8 (pt) 2021-07-27
AU2007335999A1 (en) 2008-06-26
GB0625321D0 (en) 2007-01-24
ES2445185T3 (es) 2014-02-28
CY1115178T1 (el) 2016-12-14
MX2009006378A (es) 2009-08-24
PL2115472T3 (pl) 2014-05-30
SI2115472T1 (sl) 2014-05-30
CA2671939C (en) 2017-10-03
US8460882B2 (en) 2013-06-11
RU2009127774A (ru) 2011-01-27
CA2671939A1 (en) 2008-06-26
EP2115472A1 (en) 2009-11-11
CN101675341B (zh) 2017-08-08
BRPI0720371A2 (pt) 2013-12-31
NZ577548A (en) 2012-03-30

Similar Documents

Publication Publication Date Title
GB0719792D0 (en) Cancer biomarkers
EP2089722A4 (en) BIOMARKERS
EP2009738A4 (en) ANTENNA
EP1910821A4 (en) BIOMARKER FOR OVARIAL CARCINOMA
EP1934603A4 (en) BIOMARKER FOR PROSTATE CANCER
EP2022140A4 (en) DOUBLE ANTENNA
GB0612312D0 (en) Compact antenna
EP2095464A4 (en) COMPACT ANTENNA
EP2044693A4 (en) DOUBLE AUTOMATIC DIPLEXING ANTENNA
GB0709295D0 (en) New Zealander
HK1134690A1 (zh) 子宮內膜生物標誌物
EP1907857A4 (en) BIOMARKERS OF BREAST CANCER
IL186980A0 (en) Characterizing prostate cancer
TWI340501B (en) Noise-supressing antenna assamblage
GB0623160D0 (en) Biomolecules
GB0618127D0 (en) Biomarker
HK1108924A1 (en) Cancer prognostic methods
TWI329386B (en) Antenna
GB0615902D0 (en) Antenna
GB0618429D0 (en) Cancer test
EP2210099A4 (en) BIOMARKER FOR OVARIAL CARCINOMA
EP2011187A4 (en) ANTENNA
GB0511302D0 (en) Biomarkers
EP2022500A4 (en) TUMOR SUPPRESSOR
GB2436166B (en) Liquid-coupled antenna